Clinical trial

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Recruiting now · Phase 3 · 1 countries · Registry ID NCT05569772

Recruiting nowPhase 3Interventional

What this study is about

Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexFemale
Healthy volunteersNot accepted
ConditionGlucose Intolerance After a Recent History of Gestational Diabetes

Full registry criteria

Eligible participants are women aged ≥18 years, with a history of GDM diagnosed according to the 2013 WHO criteria (at 24-32 weeks gestation or \<24 weeks for early GDM). Participants must have prediabetes diagnosed between 6 weeks and 12 months postpartum according to ADA criteria (FPG 5.6-6.9 mmol/L, 2-hour OGTT glucose 7.8-11.0 mmol/L and/or HbA1c 39-46 mmol/mol \[5.7-6.4%\]). Additional inclusion criteria include cessation of breastfeeding, no intention to become pregnant within the next year, use of effective contraception and no use of medication affecting glucose metabolism. Written ICF is obtained prior to any study-related procedures. Exclusion criteria include established diabetes, presence of autoantibodies suggestive of type 1 diabetes, normal glucose tolerance, history of pancreatitis, previous bariatric surgery or planned surgery within two years, unable to understand and speak Dutch, French or English and current pregnant or planning to become pregnant within one year after participating in the study.

Treatments and study arms

Semaglutide Pen Injector

Drug

maintenance dose of 1mg SC once weekly

Semaglutide placebo

Drug

maintenance dose of 1mg SC once weekly

Primary outcomes

Development of T2DMby 160 weeks

Defined by FPG, OGTT, and/or HbA1c according to the ADA criteria

Study locations

13 locations were listed when this page was built. The first 40 are shown.

AZORG🇧🇪 Aalst, Belgium
Katrien WierckxContact
UZA🇧🇪 Antwerp, Belgium
Niels BochanenContact
ZAS🇧🇪 Antwerp, Belgium
Ann VerhaegenContact
AZ St Jan Brugge🇧🇪 Bruges, Belgium
Sara Vandewalle, MDContact
Erasme🇧🇪 Brussels, Belgium
Maria LytriviContact
UZ Brussel🇧🇪 Brussels, Belgium
Nancy Van WilderContact
Jan Yperman🇧🇪 Ieper, Belgium
An Nollet, MDContact
AZ Groeninge Kortrijk🇧🇪 Kortrijk, Belgium
Gertjan VereeckeContact
UZ Leuven🇧🇪 Leuven, Belgium
Katrien BenhalimaContact
CHU de Liège🇧🇪 Liège, Belgium
JC PhilipsContact
Centre Hospitalier Mouscron🇧🇪 Mouscron, Belgium
Philippe OriotContact
Vitaz🇧🇪 Sint-Niklaas, Belgium
Peter CoremansContact
AZ Turnhout🇧🇪 Turnhout, Belgium
Joke Cuypers, MDContact